Social media big data could provide information on fighting prescription drug addiction

Researchers from Dartmouth, Stanford University and IBM Research have conducted a review of literature to evaluate the feasibility of using social media data to identify behavioral patterns of prescription drug abuse. Findings are published in Journal of Medical Internet Research.

"Harnessing social media platforms and data can provide insight into important novel discoveries of collective public health risk behavior, a better understanding of peoples' struggles with addiction, and their process of recovery," said lead author, Sunny Jung Kim, PhD, an e-health communication scholar in the departments of biomedical data science and psychiatry at Dartmouth's Geisel School of Medicine. "I started this project because there were few studies about why people use social networking sites to share unsolicited, highly personal information about their drug use, nor about the psychological effects or consequences of this type of user-generated communication.”

Prescription drug addiction rates have grown exponentially in recent years. Many people with these addictions are unable to receive care, so some turn to support groups through social media. In this study, researchers reviewed big data generated by social media platforms regarding personal communication and activities to develop improved public health strategies for prescription drug addiction.

“We offer theoretical applications, ethical considerations, and empirical evidence within the scope of social media communication and prescription drug abuse and addiction,” concluded Kim. “Our critical review suggests that social media big data can be a tremendous resource to understand, monitor and intervene on drug abuse and addiction problems.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.